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Fibroblast-like synoviocyte metabolism in
the pathogenesis of rheumatoid arthritis
Marta F. Bustamante, Ricard Garcia-Carbonell, Katrijn D. Whisenant and Monica Guma*
Abstract
An increasing number of studies show how changes
in intracellular metabolic pathways alter tumor and
immune cell function. However, little information
about metabolic changes in other cell types, including
synovial fibroblasts, is available. In rheumatoid arthritis
(RA), fibroblast-like synoviocytes (FLS) are the most
common cell type at the pannus–cartilage junction
and contribute to joint destruction through their
production of cytokines, chemokines, and matrix-
degrading molecules and by migrating and invading
joint cartilage. In this review, we show that these cells
differ from healthy synovial fibroblasts, not only in
their marker expression, proto-oncogene expression,
or their epigenetic changes, but also in their
intracellular metabolism. These metabolic changes
must occur due to the stressful microenvironment of
inflamed tissues, where concentrations of crucial
nutrients such as glucose, glutamine, and oxygen are
spatially and temporally heterogeneous. In addition,
these metabolic changes will increase metabolite
exchange between fibroblast and other synovial cells,
which can potentially be activated. Glucose and
phospholipid metabolism as well as bioactive lipids,
including sphingosine-1-phosphate and
lysophosphatidic acid, among others, are involved in
FLS activation. These metabolic changes likely
contribute to FLS involvement in aspects of immune
response initiation or abnormal immune responses
and strongly contribute to joint destruction.
Keywords: Fibroblast-like synovicyte, FLS, Metabolism,
Glycolysis, Bioactive lipids
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Background
Fibroblast-like synoviocytes (FLS), also known as syn-
ovial fibroblasts or type B synoviocytes, are the predom-
inant cell type comprising the structure of the synovial
intima. They are organized in two to three layers of cells
and constitute 75–80% of all synoviocytes in normal hu-
man synovium [1–3], but also in other species like rabbit
and mouse [4, 5]. FLS interact with each other and with
the extracellular matrix (ECM) via different molecules,
including α1β1 integrin, α2β1 integrin [6], and cadherin-
11, a calcium-dependent adhesion molecule, which cre-
ates a normal appearing lining [7]. In between, synovial
macrophages or type A synoviocytes are located in this
stromal cell network [8]. FLS were recently proven to be
an essential factor in the formation of a normally
organized synovial lining [8]. They have an intrinsic
capacity to establish a three-dimensional complex syn-
ovial lining architecture characterized by the multicellu-
lar organization of the compacted synovial lining and
the production of synovial fluid (SF) constituents [8].
In the inflamed rheumatoid synovium, the healthy
two- to three-layer lining structure is converted into a
pannus-like structure, a hyperplastic synovial lining con-
taining a higher number of activated FLS and macro-
phages that extends into the joint space, attaches to the
cartilage surface (cartilage–pannus junction), and in-
vades and degrades the cartilage matrix promoting joint
destruction (Fig. 1). The sublining layer contains prolif-
erating blood vessels and is invaded by inflammatory
cells such as lymphocytes, plasma cells, and macro-
phages. However, treatments that deplete or reduce
these immune populations do not always correlate with
better control of the disease. In this regard, targeting
chemokines or chemokine receptors to reduce macro-
phage infiltration in the sublining has failed to show
robust clinical improvement [9]. Treatment with the
anti-CD20 monoclonal antibody rituximab, which
significantly decreases synovial B cells after treatment,
did not strongly correlate with clinical response [10].
Yet, cadherin-11-deficient mice have a hypoplastic
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synovial lining and show a disorganized synovial reaction
to inflammation with great resistance to the induction of
arthritis and synovium hypertrophy, suggesting a critical
role of FLS in synovium architecture in both healthy and
arthritic synovial tissue [7].
We would like to further emphasize the unmet need
to target FLS in combination with current and future
therapies in rheumatoid arthritis (RA). Since Fassbender
observed that aggressive resident synovial cells invaded
and destroyed cartilage and bone in the joints of patients
with RA [11], published data suggest that synoviocytes
not only strongly respond to a pro-inflammatory envir-
onment, but also actively and autonomously drive joint
inflammation and destruction. Among animal models,
MRL-lpr/lpr mice that spontaneously develop RA-like
symptoms have synovial cells that appear to be activated,
attaching to and invading joint structures before inflam-
matory cells migrate into the synovium [12]. In addition,
in a collagen-induced arthritis model, analysis of articu-
lar tissues at earlier times showed abnormalities in the
synovium, including fibrin deposition in the joints and
synovial lining hyperplasia that precedes clinical arthritis
[13, 14]. Similarly, examination of the synovial tissues of
mice immunized with type II collagen and Complete
Freund’s adjuvant (CFA) 10 days before any clinical evi-
dence of joint swelling or tenderness showed hyperplasia
of the lining, vasodilation, and mesenchymal-appearing
cells, but no infiltration with lymphocytes or leukocytes
[15]. Supporting cellular activation in the earliest stage
of murine collagen-induced arthritis and rat adjuvant-
induced arthritis, the activated form of NF-κB was de-
tected in synovial lining cells 10 days before joint swell-
ing [16]. Although these studies do not prove that FLS
drive the disease or are the only activated cell type in
the synovium, as crosstalk between synovial fibroblasts
and resident macrophages might also play a role in FLS
activation, inflammation-independent activation of FLS
was confirmed by studies in the severe combined im-
munodeficiency (SCID) mouse model of cartilage de-
struction. In these studies, cultured human FLS and also
fibroblast-like cells isolated from SF of patients with
RA, but not those with osteoarthritis (OA), were co-
implanted with human cartilage and found to deeply
invade the co-implanted cartilage and the implanted
cartilage at a distant site [17, 18].
In RA patients, the number of FLS together with the
number of T cells were immunohistological markers in
synovial tissue of early RA patients associated with un-
favorable disease outcome, suggesting a pathogenic role
for these cells in the process of joint damage [19]. The
lack of consistent and robust clinical improvement after
immune cell targeted therapies also suggests that other
synovial cells, and not only immune cells, contribute to
chronic inflammation and also joint destruction in RA.
This hypothesis is also supported by the recent finding
that, in a subgroup of patients considered to have reached
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Fig. 1 Representative hematoxylin and eosin staining of (a) normal synovium lining, (b) rheumatoid arthritis synovium showing lining
hypertrophy, (c) normal bone/synovium interphase in normal murine ankle, (d) arthritic bone/synovium interphase in arthritis murine ankle.
Vertical lines show thickness of synovial lining. Arrows indicate pannus that migrated into the bone. Scale bars repressent 100μm
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clinical remission based on a Disease Activity Score lower
than 1.6, joint damage continued to worsen, although low-
grade inflammation could not be completely excluded [20].
Together, these findings suggest FLS play a strong role in
joint damage and chronic inflammatory-independent FLS
activation likely occurs in at least a subset of patients.
Metabolic changes after FLS activation
Multiple stimuli activate FLS in the disease initiation,
perpetuation, and terminal joint destruction phases
(Table 1 and Fig. 2). In the initiation phase, initial stimuli
such as danger-associated molecular patterns (DAMPs),
microparticles, activation of calcium channels or stimu-
lation through synovial nerves, synovial citrullination,
complement, and antibodies are also important in the
activation of the FLS. Later, the pro-inflammatory envir-
onment in RA joints, including high levels of cytokines,
growth factors, and infiltrating inflammatory cells,
further strongly activates FLS [21]. Furthermore, special
environmental conditions in the joints of patients with
RA, such as high pressure and hypoxic conditions [22],
induce changes that also play a role in FLS activation
and aggressive phenotypes.
Most of the stimuli described above that trigger the FLS
response activate a specific receptor or channel located on
the cell surface or inside the cell which, in turn, activates
signaling pathways in FLS [23–26]. Of note, many signal-
ing pathways activated under these conditions will have
profound effects on cellular metabolism to support cell
growth, differentiation, and survival. These adaptations
must be implemented in the stressful and dynamic micro-
environment of inflamed tissues. The MAPK and NF-κB
pathways, extensively studied in FLS and critical in FLS
activation and the aggressive phenotype [23–26], are also
required for an array of metabolic events, though they are
more relevant in metabolic tissues such as adipose tissue
and liver [27, 28]. Other pathways including key regulators
of metabolism in a wide variety of cell types have been
reviewed elsewhere [29, 30]. For instance, the PI3K path-
way, through AKT1 and mTOR signaling and subsequent
downstream hypoxia inducible factor 1 (HIF-1) transcrip-
tion factor activation, is a major determinant of certain
metabolic changes. The AMP activated protein kinase
(AMPK) pathway is also of importance, as it is often con-
sidered a metabolic checkpoint due to its ability to control
cell proliferation when activated under energetic stress
[31]. While some of these pathways have been shown to
decrease FLS invasive properties [32–35], further studies
are needed to link them to altered metabolism in FLS.
After activation, cells change the metabolism of all
four major classes of macromolecules (carbohydrates,
proteins, lipids, and nucleic acids) and adopt the specific
metabolic signatures required for proper effector func-
tion. The shuttling of up-regulated metabolites can also
serve as a form of intercellular communication [36, 37].
In addition, mitochondria integrate various metabolic
pathways and through this process produce intermedi-
ates needed for the synthesis of lipids, steroid hormones,
and heme, and contribute to thermogenesis [38]. Several
reviews have recently described metabolic and mito-
chondrial changes in immune and tumor cells [39–44].
However, less information is available on stromal cells,
including fibroblasts [45], and their contribution to the
pathogenesis of autoimmune diseases [46, 47]. Some of
the metabolic changes described in other cells and
conditions are summarized in Fig. 3.
Recent studies have addressed metabolic changes in the
inflamed joints of RA patients and have shown that
glucose metabolism is especially increased. Accelerated
glucose metabolism is a hallmark of proliferative and acti-
vated cells. Elevated glucose metabolism is also required
to provide sufficient amounts of metabolic intermediates
to support anabolic processes such as nucleic acid, lipid,
and protein synthesis. This up-regulation of glycolysis,
resulting in increased glucose consumption, can be
observed with clinical imaging. Several studies have shown
that fluoro-2-deoxyglucose (FDG), which is taken up by
glycolytic cells to form FDG-phosphate and can be detected
by positron emission tomography (PET), accumulates in
Table 1 FLS in disease initiation, perpetuation, and terminal
joint destruction
FLS activated via FLS response
FLS in arthritis initiation
TLR endogenous ligands
Activated complement
Autoantibodies or immune
complexes
Microparticles
Citrullination
Synoviocyte-like macrophage mediators
Mechanical stimulus
Activation markers
Changes in metabolism
Signaling pathway activation
Synovial hyperplasia
Increased expression of
adhesion molecules
FLS in arthritis perpetuation
Hypoxia
Cytokine receptors
Changes in metabolism
Bioactive metabolites
Signaling pathway activation
Adhesion molecules
Cytokine and chemokine
release
Recruitment of B and T cells
and macrophages to sublining
Increase of HLA antigen
presentation
Proteoglycan damage in
cartilage surface
Mitochondrial compensatory
response
FLS in joint destruction
Immune cell mediators (cytokines,
ligands)
Epigenetic changes, hypomethylation,
hyperacetylation
Somatic and mitochondrial mutation
Chronic metabolic changes
Tumor-like transformation
Attachment to cartilage
Migration and invasion
MMP production
RANKL expression
Resistance to apoptosis
MMP metalloprotease, RANKL receptor activator of nuclear factor kappa-B
ligand, TLR Toll-like receptor
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swollen joints [48]. Metabolic profiling of synovial tissue
showed altered glucose and also choline metabolism in RA
samples [49]. Interestingly, one study showed increase up-
take of 11C-choline in inflamed joints [50].
We have only recently begun to understand activated
metabolic pathways in RA FLS. A recent study evaluated
the characteristic metabolic profiling of RA FLS compared
to OA FLS using GC/TOF-MS [51]. Sugar metabolism
(glycolysis and pentose phosphate pathway) and amino
acid metabolism (tyrosine and catecholamine biosynthesis
and protein biosynthesis) were severely disturbed in RA
FLS compared to those in OA FLS [51]. In vitro studies
have also addressed some of these metabolic pathways
and metabolite exchange in FLS after activation.
Glucose and mitochondrial intermediate metabolites
Metabolomics studies in inflammatory arthritis, includ-
ing RA, suggest an alteration of glycolysis metabolism
given the increase of lactate in serum [52]. We evaluated
whether FLS glucose metabolism could play a role in in-
flammation and joint damage [53]. FLS stimulation with
tumor necrosis factor (TNF) or platelet derived growth
factor (PDGF) increased glucose metabolism and glucose
transporter 1 (GLUT1) expression. GLUT1 expression
also correlated with FLS baseline functions. Of interest,
glucose deprivation or glycolytic inhibitors such as 2-
deoxy-D-glucose and bromopyruvate (BrPa) impaired
cytokine secretion, proliferation, and migration, and
glycolytic inhibition by BrPa administered in vivo in a
serum transfer animal model significantly decreased
arthritis severity [53].
In the same line, another group showed that hypoxia
promoted a switch to glycolysis, supporting abnormal
angiogenesis, cellular invasion, and pannus formation
[54]. Another glycolytic inhibitor, 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one, also significantly inhibited
FLS invasion/migration, angiogenic tube formation, se-
cretion of proinflammatory mediators, and activation of
Fig. 2 Main mechanisms of FLS activation. The pro-inflammatory environment in RA joints, including high levels of cytokines, growth factors, and
infiltrating inflammatory cells, strongly activates FLS. Other stimuli, such as danger-associated molecular patterns (DAMPs), microparticles, activation of
calcium channels or stimulation through synovial nerves, complement, and antibodies are also important triggers of inflammatory signaling pathways,
metabolic shifts, and epigenetic changes. AA amino acids, PI3K phosphoinositide 3-kinase, TLR Toll-like receptor
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HIF1α, pSTAT3, and Notch-1IC under normoxic and
hypoxic conditions [54]. Zhao et al. [55] also found an
increase of glycolytic genes in collagen-induced arthritis
and human synovial and blood samples from RA
patients, showing the importance of PGK1 in the patho-
genesis of the disease. Thus, the increase of lactate ob-
served in synovial tissue could be secondary to the
glycolytic switch in FLS. Of interest, although work on T
cells in RA has shown impaired glycolytic flux in these
cells due to up-regulation of glucose-6-phosphate
dehydrogenase [56], this metabolic reprogramming does
help T cells to proliferate and differentiate toward proin-
flammatory T cells through insufficiently activating the
redox-sensitive kinase ataxia telangiectasia mutated
(ATM) [57], suggesting that each cell type requires
specific metabolic changes to become pathogenic in a
particular disease.
Glucose and other metabolites such as acetyl coen-
zyme A (acetyl-CoA) are then metabolized through the
mitochondrial tricarboxylic acid (TCA) cycle in highly
metabolic tissues, but a shift in metabolism away from
oxidative phosphorylation towards aerobic glycolysis has
also been described in inflamed tissues [58]. Interest-
ingly, roles outside metabolism have emerged for inter-
mediates of glucose metabolism and mitochondrial
TCA. For instance, lactic acid, the end product of
glycolysis, triggered FLS invasiveness [54]. Succinate is
abundant in SF from RA patients [59] and critical for
angiogenesis [60]. It also stabilizes the transcription
factor HIF-1α in activated macrophages and rat synovial
fibroblasts [61, 62]. GPR91-deficient mice, which lack a
succinate receptor, show reduced macrophage activation
and production of IL-1β in an animal model of arthritis
[59]. Finally, succinate and other metabolites, including
α-ketoglutarate, fumarate, and acetyl-CoA, are involved
in changes in the epigenome [61, 63]. These metabolic
intermediates might be expected to accumulate in FLS
under hypoxic conditions.
Choline kinase
The choline pathway is highly activated in FLS. An in-
creased level of choline kinase (ChoKα), the enzyme that
catalyzes the first step in the CDP-choline pathway and
is essential for phosphatidylcholine (PC) expression, has
been associated with malignant transformation, invasion,
and metastasis in some human cancers [64–67]. ChoKα
is also expressed in RA synovial tissue and in cultured
FLS [68]. TNF and PDGF stimulation increased ChoKα
expression and levels of PC in FLS, suggesting activation
of this pathway in the RA synovial environment. A ChoKα
inhibitor suppressed the aggressive behavior of cultured
RA FLS, including cell migration and resistance to apop-
tosis. In a K/BxN serum transfer arthritis model, pharma-
cologic ChoKα inhibition significantly decreased arthritis
in pre-treatment protocols as well as in established
disease. Interestingly, metabolomics studies correlated
Fig. 3 Metabolic alterations involved in activated cells. Activated cells take up large amounts of glucose and glutamine and divert them to the
pentose phosphate pathway (PPP) and lipid biosynthesis, respectively. Coupled to increased uptake of glycine, serine, and branched chain amino
acids (leucine, isoleucine, and valine), which are required for protein synthesis, this generates sufficient building blocks (nucleic acids, proteins,
and membranes) for proliferation. The increased generation of reactive oxygen species requires appropriate levels of antioxidants, most of which
originate from the PPP. These metabolic changes generate bioactive metabolites that are secreted, and that also contribute to cell activation.
Abbreviations: 3-PG 3-phosphoglycerate, A-KG α-ketoglutarate, CoA coenzyme A, G6P glucose-6-phosphate, LPA lysophosphatidic acid, L-AA
L-amino acids, R5P ribose-5-phosphate, S1P sphingosine-1-phosphate, PPP pentose phosphate pathway
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choline levels with inflammation in RA [52]. Related to
PC, phospholipase D (PLD) enzymes specifically cleave PC,
producing phosphatidic acid (PA) and choline. Agonist-
induced PLD activation results in PA synthesis, which is
thought to be involved in a variety of rapid cellular
responses such as cytokine secretion [69]. Several reports
suggest a pro-inflammatory role for this enzyme, suggesting
that the effects observed after ChoKα inhibition could
partially be PA-dependent [70]. The key role of PLD
enzymes in basal, IL-17-, and/or TNF-dependent expres-
sion of proinflammatory cytokines and chemokines by RA
FLS was recently investigated. PLD1-specific siRNAs and
small molecule inhibitors specific for PLD1 or PLD2 caused
a robust decrease in FLS secretion of IL-6, IL-8, and
CCL20, especially when both PLD isoforms were inhibited.
Moreover, RA synovial biopsy explants cultured in media
containing PLD isoform-specific inhibitors showed signifi-
cantly reduced constitutive secretion of IL-6 and IL-8 [70].
Bioactive lipids
Sphingosine kinase (SphK) phosphorylates sphingosine
into sphingosine-1-phosphate (S1P). S1P is a well-known
bioactive lipid, which has been involved in the pathogen-
esis of several autoimmune diseases [71]. SphK blockade
suppressed cytokines and MMP-9 release in RA periph-
eral blood mononuclear cells. In addition, downregulation
of SphK1, through either a specific siRNA approach or
transgenic human TNF SphK1-deficient mice, resulted in
significantly less synovial inflammation and joint path-
ology [72, 73]. Of interest, synovium and SF of RA
patients exhibits significantly higher levels of S1P than
their non-inflammatory OA counterparts [74].
Another study showed that activated inflammatory
arthritis SF from humans and animal models expresses
significant quantities of autotaxin (ATX), a lysophospho-
lipase D that catalyzes the conversion of lysophosphati-
dylcholine (LPC) to lysophosphatidic acid (LPA). ATX
expression from SF was induced by TNF, and LPA in-
duced SF activation and effector functions in synergy
with TNF [75, 76]. Conditional genetic ablation of ATX
in mesenchymal cells, including FLS, resulted in disease
attenuation in animal models of arthritis [77]. Notably,
high levels of LPC and low PC/LPC ratios in plasma
were shown to represent a reliable measure of inflamma-
tion [78].
Eicosanoids are other potent bioactive lipids that regu-
late FLS biology. Leukotriene B(4) (LTB(4)) is a potent
proinflammatory lipid mediator that initiates and ampli-
fies synovial inflammation in the K/BxN model of arth-
ritis [79]. FLS generate sufficient levels of LTB(4) after
TNF stimulation. Moreover, LTB(4) (acting via LTB(4)
receptor 1) was found to modulate the migratory and in-
vasive activity of FLS in vitro and also promote joint ero-
sion by pannus tissue in vivo, placing LTB(4) regulation
of FLS biology at the center of a previously
unrecognized amplification loop for synovial inflamma-
tion and tissue pathology [79]. Of interest, another ei-
cosanoid, the 15-LOX downstream product of 15-(S)-
HETE (15-S-hydroxyeicosatetraenoic acid), increased the
mRNA and protein levels of MMP-2 in RA FLS. The en-
hanced effect of 15-(S)-HETE was antagonized by the
addition of LY294002 (PI3K inhibitor) and PDTC (NF-
κB inhibitor) [80].
Other lipids, such as free fatty acids (FFA) [81], are
not only metabolic substrates but may also directly con-
tribute to articular inflammation and degradation in in-
flammatory joint diseases. Moreover, the data suggest
that, in FLS, FFA exert their effects via TLR4 and require
extracellular and intracellular access to the TLR4 recep-
tor complex. Bioactive lipids can also have anti-
inflammatory effects. For instance, phosphatidylserine
inhibits inflammatory responses in IL-1β-stimulated FLS
and alleviates carrageenan-induced arthritis in rats [82].
Metabolic changes deregulate FLS phenotype
after activation
The response after FLS activation involves changes in
the expression of genes and results in the acquisition of
new functions, such as the production of cytokines, che-
mokines, and tissue remodeling enzymes, and the ability
to proliferate, migrate, and invade cartilage. There is a
growing appreciation of the fact that reaching these acti-
vated states requires the input of new metabolites into
specific pathways and therefore there is a strong interest
in how metabolic pathways are regulated to support
these functional changes. Very limited data are available
in FLS, although we hypothesize that, similar to other
cell types, especially similar to tumor cells, metabolic
changes would support and direct the FLS aggressive
phenotype. We expect that inflammation, hypoxia, and
the need to support high-energy-demanding processes
such as migration and invasion will modify FLS metabol-
ism. In addition, fibroblasts are also critical for SF syn-
thesis, which increases, requiring energy-demanding
biosynthesis. Fighting oxidative stress would increase
flux through the pentose phosphate pathway to produce
cytoplasmic NADPH, requiring high mitochondrial
membrane potential in the conversion of matrix NADH
to NADPH. We also envision that, given the low apop-
tosis rate, these cells will have intact compensatory
mitochondrial mechanisms to respond to increased ATP
demands, increased oxidative stress, and other stress
signals for continued support of cellular functions and
survival.
Deregulation of SF
In RA, SF loses its rheological properties. This implies a
loss of lubricant properties, which are poor in RA SF,
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leading to loss of protective properties [83, 84]. This might
be due to changes in the RA SF composition. Lipidomics
studies found that RA SF has increased levels of sphingoli-
pids and phospholipids compared to normal SF. In fact,
primarily lipids that contain choline, such as phosphocho-
line, phosphatidilethanolamine, and sphingomielins, are
increased in RA SF compared with normal SF [85, 86].
These lipid compounds are likely formed in the lamellar
bodies of FLS [87]. Although phospholipids are increased
in RA, they have shorter chains [88], which are less effect-
ive in decreasing friction [89]. Lubricin levels in RA SF are
also decreased, and the molecular weight of hyaluronic
acid is lower in RA SF [88], which is less effective for SF
lubricity, turning it into a pro-inflammatory signal via the
TLR4/Myd88 pathway [90, 91]. RA SF is acidic due to
high lactate [53, 92, 93] and has a lower glucose content
than normal SF [94], likely secondary to an increase of
glucose uptake from synovial membrane as suggested by
FDG PET images [95]. Given that FLS synthesize numer-
ous cell-surface, ECM, and SF glycoproteins that are
required for maintenance of the joint, it would be of inter-
est to know how glucose or other nutrients and metabolic
changes affect the biosynthesis of glycoproteins and SF
properties [96].
Deregulation of angiogenesis
Hyperplasia of FLS leads to over-proliferation of synovial
tissue, resulting in increased oxygen consumption in
synovium, thereby forming a hypoxic environment. The
main mechanism that promotes the development of new
vessel formation is hypoxia [97, 98]. Hypoxic state leads
to the activation of HIF, which activates the expression
of HIF-responsive genes, including vascular endothelial
growth factor (VEGF), which are important in synovium
angiogenic processes and RA perpetuation [99]. VEGF
and other growth factors critical for angiogenesis, such
as angiopoetin-2, placental growth factors, or fibroblast
growth factors, are secreted by FLS and activated
synovial macrophages. Importantly, hypoxia stimulates
glycolysis and certain glycolytic enzymes, including
glucose-6-phosphate isomerase (G6PI) [100], and glyco-
lytic intermediates such as lactate [54] and succinate
[60] can be secreted outside the cells and are potent
angiogenic stimuli, thus perpetuating angiogenesis.
Attachment, migration, and invasion of cartilage
RA FLS not only become hyperplastic but also increase
their migration and mobility, invading the cartilage and
destroying it. Despite a growing understanding of the
clinical course of RA, early phases of the disease and the
specific sequences of cellular events and interactions
leading to progressive destruction of articular structures
have not been clarified. In vitro studies suggest that
damaged cartilage facilitates the attachment of cells, but
there is also evidence that the primary attachment of
FLS to matrix components such as collagens and proteo-
glycans contributes to activation of signaling pathways,
triggering their invasive behavior. Thus, a variety of
integrins, especially those of the β1 family, have been
found to be overexpressed in RA FLS, and blocking
these integrins on the surface of RA FLS reduces their
attachment and invasive capacity [101–103].
The reciprocal regulation of integrin-dependent func-
tions and cell metabolism is an emerging paradigm [104].
Metabolic pathways such as AMPK, mTORC1, and HIF
regulate integrin function on many levels, including regu-
lation of transcription, membrane traffic, and degradation.
Moreover, metabolic flux through specific pathways dir-
ectly remodels integrin function by controlling the integ-
rin glycan profile or integrin structure [104]. In turn,
integrins and integrin-derived signals control metabolic
pathways, either through engagement of specific signaling
pathways or by direct association with metabolic enzymes
such as membrane transporters. For instance, β1 integrin
interacts with CD98, a protein involved in amino acid
transport; increased amino acids levels activate mTORC1
[105]. For instance, increased glucose metabolism in
tumor cells is promoted by Twist through a β1-integrin/
FAK/PI3K/AKT/mTOR pathway [106].
Several molecules and growth factors, such as PDGF,
are essential for the formation of ECM-degrading inva-
dosomal structures and cartilage invasion and activate
several signaling pathways, including the PI3K/AKT
pathway, known to be upstream of glucose metabolism
[107]. Also, FLS secrete collagenases and metallopro-
teases (MMP), such as MMP-9, that start degrading
cartilage ECM after activation [108]. Other MMP in-
volved are MMP-13 [109], MMP-1 [110], MMP-2 [111],
and MMP-3. The intimal lining is the major source of
MMPs in RA, and in situ hybridization studies localize
collagenase messenger RNA almost exclusively to FLS.
As described above, the expression of some of these
MMP (MMP-1 and MMP-3) in FLS in vitro is modified
by glucose or choline metabolism inhibition [53, 68]. Fi-
nally, as in angiogenesis, some of the glycolytic enzymes,
including glucose-6-phosphate isomerase (G6PI) [100]
and glycolytic intermediates such as lactate and succin-
ate [54], induce FLS invasion.
Apoptosis versus proliferation
The mechanisms of intimal lining hyperplasia remain
controversial. While active proliferation is one explan-
ation, and some proto-oncogenes, such as c-myc, are
expressed in FLS, the lack of mitoses and absence of im-
munohistochemical staining for some nuclear prolifera-
tion markers suggest that local cell division might not
significantly contribute to the increased number of cells.
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Resistance to apoptosis
Resistance to programmed cell death (apoptosis) induced
by the apoptotic stimulus signals, which are abundant in
the inflamed joint, is a prominent characteristic of RA FLS.
Apoptosis is a mechanism by which cells undergo death to
control cell proliferation or in response to DNA damage.
RA FLS exhibit changes in mitochondrial pathways of
apoptosis and are resistant to receptor-mediated apoptosis
at multiple levels. Several explanations have been proposed,
including deregulation of the Bcl-2 family of proteins crit-
ical to intrinsic pathway regulation [112, 113], deregulation
of the NF-κB signaling pathway [114], p53 mutations, and
low expression of PUMA, were found in RA synovium and
FLS, which provides an explanation for the lack of p53-
induced FLS apoptosis [115, 116]. The role of metabolism
on apoptosis and mitochondrial response in other cell
types, especially tumor cells, has been extensively studied
[117, 118]. Among other mechanisms, essential glycolytic
enzymes can be translocated into the nucleus, where they
play roles independent of their canonical metabolic roles,
including anti-apoptosis, providing a possible link between
metabolism and apoptosis. For instance, hexokinase 2
(HK2), which phosphorylates glucose to produce glucose-
6-phosphate, binds to the mitochondrial membrane via its
interaction with the outer membrane porin protein voltage-
dependent anion channel (VDAC) [118]. The interaction
between HK2 and VDAC inhibits the release of intermem-
brane pro-apoptotic proteins, thereby protecting cells from
apoptosis. Of interest, the expression of HK2 is increased in
RA FLS compared to OA FLS [53], and might play a role
in FLS apoptosis resistance. Also, RA FLS have a higher
glycolytic rate with increased anaerobic respiration and
lactate production. This lactate acidifies the ECM, an event
that protects it from apoptosis through the regulation of
calcium mobilization in capsaicin-induced apoptosis in
synoviocytes [119].
Altered autophagy
Autophagy is an endogenous process necessary for the
turnover of organelles, maintaining cellular homeostasis
and directing cell fate. Mitophagy or autophagy of mito-
chondria is required to eliminate dysfunctional mito-
chondria and is critical to maintain appropriate
metabolic and cell survival signals. Increased mitophagy
or autophagy provides survival advantage to the cells in
nutrient-deprived or hypoxic conditions. In fact RA FLS
showed an increase of genes involved in autophagy, such
as beclin-1 and LC3, which inversely correlates with
their apoptosis rate [120]. In addition, RA FLS under
endoplasmic reticulum stress might resist against apop-
tosis increasing autophagy [121]. However, we lack infor-
mation regarding whether or not RA FLS mitochondria
have up-regulated some compensatory mitochondrial
mechanisms, including mitophagy, to further resist
against apoptosis. Further studies are needed to under-
stand the tangled relationship between mitochondria,
apoptosis, and autophagy in FLS.
Crosstalk with synovial cells
No cell type explains the pathologic behavior of RA
synovial tissue. Rather, it is the interactions between
these cells that define the disease. These various cell
types can interact in two general ways: first, through
secreted mediators and through direct cell–cell contact
that is mediated by cell surface receptors and ligands.
Metabolic changes will modify metabolite exchange be-
tween cells and can potentially help in RA chronic
inflammation. As mentioned above, intermediates of glu-
cose metabolism and mitochondrial TCA have extracel-
lular functions, including angiogenesis, invasiveness, and
antiapoptosis [122]. Amino acids, including branched
amino acids, have been shown to affect cell signaling
(e.g., mediating the mTOR pathway) [123]. Yet another
example is kynurenine, a tryptophan metabolite gener-
ated by indoleamine 2,3-dioxygenase (IDO) which stim-
ulates TH2 polarization and Treg cell recruitment [124].
Finally, glutathione released by dendritic cells is cleaved
to cysteine, which promotes effector T cell proliferation
[125]. Lipid signaling can occur via activation of a
variety of receptors, including G protein-coupled and
nuclear receptors, and members of several different lipid
categories have been identified as signaling molecules
and cellular messengers [126]; examples include
sphingosine-1-phosphate, the inositol phosphates de-
rived from the phosphatidylinositolphosphates (PIPs), di-
acylglycerol, short fatty acids, eicosanoids, and the
oxysterols, such as 25-hydroxy-cholesterol, which are
liver X receptor agonists.
In arthritic synovium, although no specific co-culture
studies have been described, some of the above-
mentioned intermediate metabolites that stimulate FLS,
including succinate or lactate, are known to be secreted
by cells present in the synovium like macrophages and
might work through both autocrine and paracrine mech-
anisms. Further studies are needed to know whether the
above or other mechanisms play a role in the crosstalk
between FLS and other synovial cell types.
Epigenetics
Epigenetic changes are changes in gene function that are
heritable over generations without altering the DNA
sequence. Short-lived chromatin modifications can also
substantially alter gene function and indirectly initiate herit-
able epigenetic changes of the genome. There are three
main mechanisms—DNA methylation, histone modifica-
tion, and expression of microRNAs—with significant cross-
regulation [127]. Epigenetic mechanisms recently raised
great interest in the study of the pathogenesis of chronic
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diseases [128–131]. Accumulating data suggest that epigen-
etic changes in stromal cell populations might be crucially
involved in RA pathology, as epigenetic mechanisms are in-
volved in FLS aggressive phenotype [127, 132]. The recipro-
cal interaction between metabolism and epigenetics is an
emerging field of study; there is a dynamic relationship
between metabolic processes and gene regulation via the
remodeling of chromatin. Most chromatin-modifying
enzymes use cofactors, which are products of metabolic
processes. For instance, cofactors such as succinate, nico-
tinamide adenine dinucleotide (NAD), acetyl-CoA, S-ade-
nosyl methionine, α-ketoglutarate, or flavin adenine
dinucleotide (FAD), have critical roles in regulating chro-
matin processes [133]. Emerging evidence suggests that en-
vironmental factors, including lifestyle and diet, might
cause epigenetic changes resulting in long-term changes in
organ function. For instance, choline, the plasma levels of
which correlate with dietary amount, has been implicated
as an epigenetic modifier of the genome that may alter gene
methylation, expression, and cellular function [134]. Over
the past decade, multiple studies have also shown that
nutrition can alter the metabolic phenotype of offspring,
raising the question of how metabolism regulates the epige-
nome of germ cells [135].
Conversely, some epigenetic factors have been shown
to regulate metabolic genes leading to a shift in energy
flow. For instance, emerging evidence now indicates that
microRNAs play a significant role in regulating the
expression and activity of peroxisome proliferator-
activated receptors (PPARs), which control the transcrip-
tion of genes involved in energy homeostasis [136].
MicroRNAs also regulate expression of genes involved
in several aspects of cell metabolism, including glycolysis
and the mitochondrial TCA cycle, and were shown to
have a major impact on signal transduction via PI3K/
AKT and HIF1 [137, 138]. DNA methylation and histone
modifications were also shown to modulate the expres-
sion of metabolic genes, including gluconeogenesis
enzymes and sirtuins, respectively [139]. A detailed
study of the epigenetic–metabolism crosstalk in FLS
could explain why RA FLS early in the initiation or later
in the chronic phase of the disease might produce high
levels of disease-promoting molecules without further
stimulation by immune cells.
Conclusions
Most of the therapies approved for RA do not directly tar-
get FLS. Biological therapies that focus on inhibiting im-
mune cell activation or inflammatory cytokines likely
improve the inflammation-dependent FLS activation but
do not address the chronic inflammatory-independent
FLS activation observed in a subset of patients. Repro-
gramming metabolic changes might be a new modality
key to developing joint-protective strategies in RA FLS. In
fact, the metabolic rewiring of immune cells has been
viewed as a promising source of novel drug targets [37,
140]. Resetting metabolism in these cells as well and in
stromal cells contributing to pathogenesis offers novel
opportunities for disease modulation in RA. In fact, rheu-
matologists already use the antimetabolites methotrexate
and leflunomide for the treatment of patients with inflam-
matory arthritis. And both were shown to inhibit FLS
functions [141, 142]. Biological therapies including anti-
TNF therapies could also address metabolic changes in-
duced by inflammation, although further studies are
needed to link their efficacy to altered metabolism in FLS.
Inhibition of key enzymes that regulate activated pathways,
including glycolysis (BrPa or PFKFB3 inhibitor) or phospho-
lipid (ChoK inhibitor) metabolism, would be one way to
interfere with these metabolic changes and end products
such as lactate, succinate, or bioactive lipids. Other ways to
modulate cell and specifically mitochondrial metabolism
would be by targeting mitochondria via enhancing mito-
chondrial biogenesis or by encouraging reliance on oxidative
phosphorylation instead of glycolysis. AMPK agonists could
improve mitochondria biogenesis if needed. Furthermore,
understanding whether there are disease-specific changes in
metabolism, or activation of specific changes in metabolic
pathways such as mTOR or HIF1a, could lead to identifica-
tion of key regulatory enzymes or factors as new therapeutic
targets. Thus, further characterization of the mechanisms
linking cellular metabolism and mitochondrial function is
needed to obtain clearer insight into the relationship
between mitochondrial homeostasis, metabolic changes, and
inflammation in FLS. Whether this truly constitutes an
option to increase the drug armamentarium in rheumatic
diseases beyond biological and kinase inhibitor therapies
remains to be determined.
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